At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
Romosozumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate the Effect of AMG 785 on Parameters of Bone Quality of the Forearm Using pQCT in Postmenopausal Women With Low Bone Mineral Density
In Brief
A Phase 1 clinical trial evaluating Romosozumab and Placebo for Osteopenia. Completed, enrolled 24 participants.
Detailed Summary
The purpose of this study is to evaluate the effect of romosozumab on parameters of bone quality of the forearm using peripheral quantitative computed tomography (pQCT) following multiple subcutaneous dose administrations of romosozumab in postmenopausal women with low bone mass.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteopenia
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2009
Enrollment StartAug 2009
Primary CompletionAug 2010
TodayJul 2026
First PostedAug 3, 2009
Enrollment StartAug 18, 2009
Primary CompletionAug 19, 2010
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 16.9 years ago
Interventions
Romosozumabdrug
Administered by subcutaneous injection
Placebodrug
Administered by subcutaneous injection